FACTin treatment of IPF hPCLS reduced the levels of the fibrotic markers COL1A1, FN1, smooth muscle actin alpha 2 (ACTA2), the mesenchymal marker vimentin (VIM), as well as HMGA2 and pH2A.X. This evidence concerns the gene ACTA2 and idiopathic pulmonary fibrosis.